Menu

Creatine and Ubiquinol for Sperm Quality (CRESPAQ10)

Status

Completed

Conditions

Oligospermia
Sperm Count, Low

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Supplement 2
Dietary Supplement: Supplement 1

Study type

Interventional

Funder types

Other

Identifiers

NCT06202469
CR-24-AK15

Details and patient eligibility

About

This randomized controlled double-blind parallel-group interventional trial explores the impact of 8-week creatine supplementation, with or without ubiquinol, on sperm quality biomarkers in normospermic and oligospermic men. It aims to determine potential enhancements in sperm health to provide insights into male fertility and reproductive health improvement strategies.

Enrollment

18 patients

Sex

Male

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 18 - 35 years
  • Sperm quality test available (at least half will have low sperm quality)
  • Informed consent
  • Healthy BMI (18.5 - 24.9 kg/m2)

Exclusion criteria

  • Major chronic disease and acute injuries
  • History of dietary supplement use during the past 28 days
  • No consent to randomization
  • Participation in other studies

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

18 participants in 3 patient groups, including a placebo group

Supplement 1
Experimental group
Description:
Creatine monohydrate
Treatment:
Dietary Supplement: Supplement 1
Supplement 2
Experimental group
Description:
Creatine monohydrate plus ubiquinol
Treatment:
Dietary Supplement: Supplement 2
Placebo
Placebo Comparator group
Description:
Inulin
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

Sergej Ostojic, MD, PhD

Timeline

Last updated: Dec 04, 2024

Start date

Dec 15, 2023 • 1 year and 4 months ago

End date

May 31, 2024 • 11 months ago

Today

May 07, 2025

Data sourced from clinicaltrials.gov